Posters

Comparison of the efficacy of intravitreal ranibizumab and aflibercept in the treatment of diabetic macular edema

Poster Details

First Author: M.Batur TURKEY

Co Author(s):    H. Urak   E. Seven   S. Tekin   T. Yasar                    

Abstract Details



Purpose:

We aimed to compare the results of intravitreal ranibizumab and intravitreal Aflibercept injection for visual acuity (VA), retinal thickness and possible complications in treatment of diabetic macular edema (DME).

Setting:

Yuzuncu Yil University, Department Of Ophthalmology

Methods:

In this prospective study, 52 eyes of 36 patients were included. The patients were randomly divided into two groups. Each group included 26 eyes of 18 patients treated with intravitreal injection. All patients were examined preoperatively and after 3-doses of intravitreal injection postoperatively. Fasting blood glucose (FBG) and HbA1c values were recorded before injection. Best corrected visual acuity (BCVA), intraorbital pressure (IOP), central macula thickness (CMT) and parameters of retinal layers were recorded. These parameters and related complications were compared preoperatively and after 3-doses of injection postoperatively 1 month.

Results:

The average duration of diabetes mellitus was 10.84±5.39 (3-23) years in ranibizumab group and 12.38±5.52 (1-22) years in Aflibercept group (p=0,314). Average age were 60,69±7,49 (50-78) in ranibizumab and 57,76±6,61(43-69) years in Aflibercept group (p=0,142). Average FBG value was 223,33±113,17 (122-528) mg/dL in ranibizumab group and 197,30±102,29 (91-490) mg/dL in Aflibercept group (p=0,431). The average of HbA1c values were 9,35±2,3 (7-13) and 9,41±2,0 (5.9-13.7) respectively (p=0,921). In group of ranibizumab injection, preoperative and postoperative 1-month BCVA were found 0,64±0,46(0,1-1,3) and 0,55±0.41 (0.05-1.51) LogMAR respectively (p=0,308). The average IOB were calculated 13.31±3.17 (10-22) mmHg and 15.73±5.34 (10-34) mmHg respectively (p=0,045). CMT were found 503,31±174,36 (142-860) µm and 356,26±81,7(250-535) µm respectively (p<0,001). BCVA values before and 1-month after treatment with Aflibercept were found 0,49±0,40 (0.0-1.3) LogMAR and 0,30±0,26 (0.0-1.0) LogMAR respectively (p=0,001). Average value of CMT was 449,42±128,91(252-746) µm and 301,84±66,31(212-514) µm respectively (p=0,00).

Conclusions:

In this study, successful results were achieved for functionally accuracy with both intravitreal injection agents. However more extensive randomised controlled studies with long-term follow-up are needed in order to evaluate the effectiveness and the safety of these agents.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy